This approach uses mesenchymal stem cells isolated from a patient’s own fat tissue to treat neurodegenerative diseases. The stem cells are supposed to assist in repair of damaged tissue and ...

Lecanemab binds protofibrils more tightly than fibrils, perhaps explaining lower ARIA rate. Use of plasma biomarkers brings down trial screening cost. Lecanemab has been selected for the first amyloid ...

As the baby boom generation reaches its hopefully golden years, scientists have been projecting a doubling of dementia cases in the U.S. by 2050, alarming health care agencies, the public, and health ...

On Tuesday September 10, Francisco Lopera died of cancer at his home in Medellin, Colombia. He was 73, and only just beginning to see his life’s work come to fruition. In fact, Lopera still had much ...

It has been clear for a while that anti-amyloid antibodies can sweep plaque from the brain, but until now the question of whether this slows cognitive decline has remained hotly contended. Despite ...

Many people on aducanumab (trade name Aduhelm) develop the amyloid-related imaging abnormalities (ARIA) that mark fluid retention and microhemorrhages in the brain. In the November 22 JAMA Neurology, ...

In a watershed moment for the field, the U.S. Food and Drug Administration today approved the first Alzheimer’s treatment that tackles the underlying disease pathology. Biogen and Eisai’s anti-amyloid ...

While scientists know that age-related hearing loss increases a person’s risk of dementia, their view of how vision loss affects cognition is fuzzy. It may be coming into focus, though. Recently, ...

A potential treatment for Alzheimer’s disease relies on 40 Hz light or sound to entrain gamma rhythms in the brain. This intervention, pioneered by Li-Huei Tsai and colleagues at Massachusetts ...

For decades, the U.S. Food and Drug Administration has taken a light touch to regulating diagnostic tests that use body fluids or tissues. Such assays, very much including cerebrospinal fluid and ...

The slight slowing of cognitive decline achieved by Leqembi and perhaps by Aduhelm has revived debate around how much change is needed to be “clinically meaningful.” Two recent papers—one a report ...

Change was in the air at the Alzheimer’s Association International Conference, held July 16-20 in Amsterdam. With the first treatment in 20 years having just earned traditional approval from the U.S.